Literature DB >> 16092097

Toward future therapies in progressive supranuclear palsy.

David J Burn1, Naomi M Warren.   

Abstract

There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16092097     DOI: 10.1002/mds.20546

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

1.  Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.

Authors:  Deniz Kahraman; Carsten Eggers; Harald Schicha; Lars Timmermann; Matthias Schmidt
Journal:  J Neurol       Date:  2011-07-13       Impact factor: 4.849

2.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

3.  Multireceptor fingerprints in progressive supranuclear palsy.

Authors:  Wang Zheng Chiu; Laura Donker Kaat; Agnita J W Boon; Wouter Kamphorst; Axel Schleicher; Karl Zilles; John C van Swieten; Nicola Palomero-Gallagher
Journal:  Alzheimers Res Ther       Date:  2017-04-17       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.